Imaging in pulmonary infections of immunocompetent adult patients.
Journal
Breathe (Sheffield, England)
ISSN: 1810-6838
Titre abrégé: Breathe (Sheff)
Pays: England
ID NLM: 101231007
Informations de publication
Date de publication:
Mar 2024
Mar 2024
Historique:
received:
06
11
2023
accepted:
06
02
2024
medline:
10
4
2024
pubmed:
10
4
2024
entrez:
10
4
2024
Statut:
ppublish
Résumé
Pneumonia is a clinical syndrome characterised by fever, cough and alveolar infiltration of purulent fluid, caused by infection with a microbial pathogen. It can be caused by infections with bacteria, viruses or fungi, but a causative organism is identified in less than half of cases. The most common type of pneumonia is community-acquired pneumonia, which is caused by infections acquired outside the hospital. Current guidelines for pneumonia diagnosis require imaging to confirm the clinical suspicion of pneumonia. Thus, imaging plays an important role in both the diagnosis and management of pneumonia, with each modality having specific advantages and limitations. Chest radiographs are commonly used but have limitations in terms of sensitivity and specificity. Lung ultrasound shows high sensitivity and specificity. Computed tomography scans offer higher diagnostic accuracy but involve higher radiation doses. Radiological patterns, including lobar, lobular and interstitial pneumonia, provide valuable insights into causative pathogens and treatment decisions. Understanding these radiological patterns is crucial for accurate diagnosis. In this review, we will summarise the most important aspects pertaining to the role of imaging in pneumonia and will highlight the imaging characteristics of the most common causative organisms.
Identifiants
pubmed: 38595938
doi: 10.1183/20734735.0186-2023
pii: EDU-0186-2023
pmc: PMC11003523
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
230186Informations de copyright
Copyright ©ERS 2024.
Déclaration de conflit d'intérêts
Conflict of interest: S. Pochepnia has received honoraria from Boehringer Ingelheim outside the scope of this article. H. Prosch has received honoraria from AstraZeneca, BMS, Boehringer Ingelheim, Bracco, Daiichi Sankyo, Janssen, MSD, Novartis, Roche, Sanofi, Siemens Healthineers and Takeda outside the scope of this article. E.M. Grabczak, E. Johnson, F.O. Eyuboglu and O. Akkerman declare no potential conflicts of interest.